Sell Your Home Health Agency in California (2026): Multiples, PE Buyers, CHOW & Compliance Mechanics - CT Acquisitions
Start a Conversation

Sell Your Home Health Agency in California (2026): Multiples, PE Buyers, CHOW & Compliance Mechanics

Sell Your Home Health Agency in California

Home health and hospice in California: caregiver visiting elderly patient, in-home nursing, PE roll-up activity

If you operate a Medicare-certified home-health, non-medical home-care, or hospice business in California and you have searched “sell my home health agency in California”, the variables that drive your sale price are state-specific and sub-vertical-specific in ways the national category data does not capture. Your state health department license, your CMS 855A Medicare enrollment status, the Change of Ownership (CHOW) timeline for the 855A novation in your CMS region, your state’s Medicaid HCBS waiver participation requirements, your state’s CON (Certificate of Need) status (which creates a premium-multiple moat in NC, GA, AL, MS, KY, WV, AR, IL, MI, NJ, NY, OH, PA, SC, TN, VA, WA, and others), the EVV (Electronic Visit Verification) compliance picture, your DOJ False Claims Act tail liability exposure (massive in hospice), your hospice cap recoupment risk if your average length of stay exceeds 180 days, your Medicare star rating, your caregiver turnover relative to industry benchmarks, your payer mix concentration, and the named public strategics plus PE platforms with active deal posture in California in 2026 all reshape the multiple a buyer will pay. This page walks through the California valuation framework as Medicare-certified home-health, non-medical home-care, and hospice businesses are actually trading in mid-2026, the named buyers actively acquiring here, and the 18 to 24 month pre-sale playbook that converts an owner-operator agency into a platform-multiple sale.

CT Acquisitions runs a sell-side M&A advisory practice across a $2026 home-health, home-care, and hospice market that has experienced a generational restructuring. The UnitedHealth Optum acquisition of Amedisys for $3.3 billion closed August 7-14 2025 (NOT pending, NOT blocked) after a Maryland federal court approved a DOJ settlement requiring 164 location divestitures across 19 states ($528M annualized revenue) to Pennant Group ($146.5M for 54 locations) and BrightSpring ($239M for 107 locations). The Enhabit / Kinderhook Industries take-private closed May 18 2026 at $1.1 billion / $13.80 per share / 10.2x trailing EBITDA, definitively resetting post-PDGM home-health-plus-hospice platform multiples at the 10x level. General Atlantic acquired TEAM Services Group from Alpine Investors at $3 billion / ~10x EBITDA in April 2026. Bristol Hospice (Webster Equity) launched an active auction in March 2026 marketed on $140 million EBITDA with sponsor bids topping $1 billion. The PE platform pool has consolidated around six high-velocity acquirers (Help at Home under Centerbridge + Vistria with active $3B+ exit exploration, AccentCare under Advent International, Compassus under TowerBrook + Ascension Health 50/50, Three Oaks Hospice under Martis Capital since October 2024, Synergy HomeCare franchisor under Levine Leichtman since January 21 2025, and HomeWell Care Services under Main Post Partners since January 21 2026). BAYADA Home Health Care is a nonprofit 501(c)(3) foundation since January 2019 — NOT CVC Capital, NOT any PE sponsor — which is the most common error in the M&A press for this sector. Whether you are looking at a $400K SDE single-branch home-health agency, a $3M EBITDA hospice with 80-100 day average length of stay, or a $15M EBITDA platform-quality multi-state home-care book, the California context matters before the data room opens.

The California home-health, home-care, and hospice landscape in 2026

The US home-health, home-care, and hospice market runs roughly $130-150 billion in annual revenue across Medicare-certified home-health (the largest single channel), Medicare hospice benefit, Medicaid HCBS waiver-funded home-care, VA Aid & Attendance, long-term care insurance, and private pay. The market is post-PDGM (Patient-Driven Groupings Model since January 1 2020), post-HHVBP nationwide expansion (Home Health Value-Based Purchasing effective January 1 2025), post-HOPE (Hospice Outcomes & Patient Evaluation effective October 1 2025), and post-VBID-end (Hospice carve-in discontinued December 31 2024; full VBID model ended December 31 2025).

California home-health and hospice owners are pricing their businesses in a market where the spread between an owner-operator local agency and a $15M+ EBITDA platform seller is structural rather than cyclical — the spread compounds because multi-state license footprint, EMR/clinical doc standardization on enterprise systems (Homecare Homebase, MatrixCare, WellSky, Axxess, Netsmart), Medicare 4+ star rating, caregiver turnover under industry benchmark, and clean DOJ False Claims Act history cannot be replicated overnight. The aging-population tailwind (the 65+ population grew from ~46 million in 2014 to ~63 million by 2026, with the 85+ subset growing 2-3x faster) drives sustained demand growth that public strategics and PE platforms are pricing into multi-year deal volume.

Home-health, home-care, and hospice M&A multiples in 2026 spread across three distinct sub-vertical bands that owners conflate at their peril. Hospice prices highest at 11-15x EBITDA for platform-quality sellers because of per-diem economics, 20-35% EBITDA margins, and intense PE plus strategic competition. Medicare-certified home-health prices mid-range at 9-12x EBITDA for platforms after the post-PDGM market reset in 2020 brought multiples down from the 12-14x pre-PDGM range. Non-medical home-care prices lowest at 8-11x EBITDA for platforms with the General Atlantic acquisition of TEAM Services Group from Alpine Investors at ~10x EBITDA ($3 billion / ~$300M EBITDA in April 2026) anchoring the band. Add-ons across all three sub-verticals price 2-4 turns below platform multiples. The single most consequential 2026 transaction is the Enhabit / Kinderhook Industries take-private that closed May 18 2026 at $1.1 billion / $13.80 per share / 10.2x trailing EBITDA on ~$108M EBITDA and ~$1.06B revenue, which definitively reset post-PDGM home-health-plus-hospice platform multiples at the 10x level. The UnitedHealth Optum / Amedisys $3.3 billion acquisition closed August 7-14 2025 (NOT pending, NOT blocked) after a Maryland federal court approved a DOJ settlement requiring 164 location divestitures across 19 states ($528M annualized revenue) to Pennant Group ($146.5M for 54 locations) and BrightSpring ($239M for 107 locations). DOJ final judgment entered December 2025. Other consequential 2024-2026 transactions include Addus HomeCare / Gentiva personal care ($350M December 2 2024, $280M annualized revenue across AZ, AR, CA, MO, NC, TN, TX), VITAS Healthcare / Covenant Health hospice ($85M April 17 2024, FL panhandle + AL), Aveanna Healthcare / Thrive Skilled Pediatric Care (June 4 2025, 23 pediatric locations across 7 states), Three Oaks Hospice / Martis Capital (~$150M October 2024), Synergy HomeCare franchisor / Levine Leichtman Capital Partners (January 21 2025), and HomeWell Care Services / Main Post Partners (January 21 2026, first PE sponsor for the 138-agency franchise).

What is specific to California

California concentrates the five state-specific home-health and home-care variables that dominate any sale process. SB 525 healthcare worker minimum wage (signed October 13 2023, effective for most facilities October 16 2024 and county facilities January 1 2025) puts home-health agencies on a path to $25 per hour over 2-9 years depending on facility class — this materially affects every CA home-health agency’s labor cost dynamics and buyer-side EBITDA underwrite. HCAI (formerly OSHPD) provides state oversight for home-health agencies. CDSS Home Care Aide Registry is required for non-medical home-care workers. CalAIM transition 2022-2025 has expanded community-based services under the Medi-Cal managed care framework (9+ managed care plans statewide). In-Home Supportive Services (IHSS) is California’s publicly-funded personal care program serving ~600,000 consumers with ~550,000 providers (mostly family members), the single largest program in the state’s home-care economy — it affects private home-care wage benchmarks but does not compete directly with private agencies (different consumer base). The AB 1672 (2024) IHSS overtime law maintained the legacy overtime cap structure. 1099 misclassification exposure is the single biggest non-FCA tail liability in California home-care, with the Care Specialist HCS Inc. $10M+ judgment in 2024-2025 from the California Attorney General setting the precedent. The dominant SF Bay Area, LA basin, and San Diego biotech corridor markets each carry distinct buyer dynamics; active acquirers include AccentCare (Advent), Help at Home, BAYADA nonprofit, Compassus (TowerBrook + Ascension) via the Providence Health JV across CA/OR/WA, and Honor/Home Instead.

Valuation multiples for California home-health, home-care, and hospice businesses in 2026

The 2026 buyer map: for the full sponsor-by-sponsor cap-table of the 32 active US home health, home care, and hospice PE platforms acquiring in California and across the US in 2024-2026, with primary CMS, SEC, MedPAC, and sponsor-portfolio citations on every claim, see the 2026 Home Health PE Roll-Up Tracker.

Home-health, home-care, and hospice M&A multiples in 2026 spread across three distinct sub-vertical bands that owners conflate at their peril. Hospice prices highest at 11-15x EBITDA for platform-quality sellers because of per-diem economics, 20-35% EBITDA margins, and intense PE plus strategic competition. Medicare-certified home-health prices mid-range at 9-12x EBITDA for platforms after the post-PDGM market reset in 2020 brought multiples down from the 12-14x pre-PDGM range. Non-medical home-care prices lowest at 8-11x EBITDA for platforms with the General Atlantic acquisition of TEAM Services Group from Alpine Investors at ~10x EBITDA ($3 billion / ~$300M EBITDA in April 2026) anchoring the band. Add-ons across all three sub-verticals price 2-4 turns below platform multiples. The single most consequential 2026 transaction is the Enhabit / Kinderhook Industries take-private that closed May 18 2026 at $1.1 billion / $13.80 per share / 10.2x trailing EBITDA on ~$108M EBITDA and ~$1.06B revenue, which definitively reset post-PDGM home-health-plus-hospice platform multiples at the 10x level. The UnitedHealth Optum / Amedisys $3.3 billion acquisition closed August 7-14 2025 (NOT pending, NOT blocked) after a Maryland federal court approved a DOJ settlement requiring 164 location divestitures across 19 states ($528M annualized revenue) to Pennant Group ($146.5M for 54 locations) and BrightSpring ($239M for 107 locations). DOJ final judgment entered December 2025. Other consequential 2024-2026 transactions include Addus HomeCare / Gentiva personal care ($350M December 2 2024, $280M annualized revenue across AZ, AR, CA, MO, NC, TN, TX), VITAS Healthcare / Covenant Health hospice ($85M April 17 2024, FL panhandle + AL), Aveanna Healthcare / Thrive Skilled Pediatric Care (June 4 2025, 23 pediatric locations across 7 states), Three Oaks Hospice / Martis Capital (~$150M October 2024), Synergy HomeCare franchisor / Levine Leichtman Capital Partners (January 21 2025), and HomeWell Care Services / Main Post Partners (January 21 2026, first PE sponsor for the 138-agency franchise).

Home-Health (Medicare-certified) multiples by EBITDA band

Home-Care (non-medical) multiples by EBITDA band

Hospice multiples by EBITDA band

Premium drivers (+0.5x to +2.0x)

Discount drivers (-0.5x to -2.0x)

Why California home-health, home-care, and hospice recurring revenue prices differently than it reads on paper

Recurring revenue mechanics fracture sharply across the three sub-verticals because each operates under a different CMS payment model. Home-health bills under the Patient-Driven Groupings Model (PDGM) since January 1 2020 with 30-day episode periods (down from 60-day pre-PDGM), 432 case-mix groups per CY2025, and a CY2025 base 30-day payment of approximately $2,058.71 nationally before wage index. Five PDGM case-mix variables determine the episode rate: timing (early vs late), admission source (community vs institutional), clinical grouping (12 clinical groupings), functional impairment level, and comorbidity adjustment. The Low Utilization Payment Adjustment (LUPA) threshold at 5 or fewer visits per 30-day period currently affects 7-9% of episodes and pays per-visit instead of episode-rate. The Home Health Value-Based Purchasing (HHVBP) program expanded nationwide January 1 2025 with a +/-5% payment adjustment based on quality performance. Hospice bills per-diem at four levels of care: Routine Home Care (RHC) days 1-60 at $231.16 per day and days 61+ at $182.55 per day, Continuous Home Care at $66.97 per hour, Inpatient Respite Care at $533.51 per day, and General Inpatient Care at $1,255.43 per day. 96-97% of hospice days are RHC. The Service Intensity Add-On (SIA) pays additional for skilled visits during the last 7 days of life. The FY2026 hospice cap is $35,361.44 per beneficiary (up 2.7% from $34,465.34 FY2025), with the cap year running October 1 through September 30. Home-care bills hourly: 2026 rates run $28-42 per hour private pay, $20-32 per hour Medicaid HCBS, $24-38 per hour VA Aid & Attendance, and $26-40 per hour LTC insurance. Live-in and 24-hour rates run $300-450 per day private pay and $240-360 per day Medicaid where allowed. The Medicare Advantage share of Medicare beneficiaries reached approximately 55% by 2026, and MA plans typically pay home-health 10-20% less per episode than FFS via negotiated case rates. The VBID Hospice carve-in DISCONTINUED December 31 2024 with the full VBID model ending December 31 2025; from January 1 2026 onward, hospice care reverts to FFS Medicare regardless of MA enrollment.

Sub-vertical CMS payment mechanics summary

Contingent consideration mechanics for California home-health, home-care, and hospice sellers

Contingent consideration in home-health, home-care, and hospice deals operates under an unusually wide tail-liability universe that drives aggressive buyer indemnity demands. DOJ False Claims Act tail liability is the single biggest hospice-specific underwrite variable: Traditions Health paid $34 million in October 2024 for non-medically necessary home-health services plus physician-medical-director kickbacks (which is why Traditions home-health was sold to VitalCaring in December 2025 as a distressed sale post-FCA); Curo Health Services paid $25 million historically pre-Humana acquisition; AccentCare / Guardian Hospice paid $3 million in 2024 in Georgia for non-terminal hospice patients; VITAS paid $3.9 million in 2014 in Tennessee and Virginia for non-terminal patients. These FCA settlements show up at buyer-side QofE as either named historical settlements (priced into the indemnity structure) or open whistleblower complaints (which trigger material adverse change clauses). State Medicaid recoupment exposure is parallel: Texas HHSC payment audits via TMHP claw back personal care service billings for EVV non-compliance, New York DOH personal care audits and CDPAP fiscal intermediary documentation audits routinely find 5-15% of claims pulled back, California DHCS audits IHSS providers and CDSS audits home-care aide registry compliance, and Florida AHCA SMMC LTC plan audits drive recoupment via plan capture. CMS audit pipeline: UPIC (Unified Program Integrity Contractor, primary fraud-focused contractor since 2018 consolidation, 5 regions) probes approximately 5% of HH/hospice claims annually; TPE (Targeted Probe and Educate) runs 3 rounds before referral to UPIC; RAC (Recovery Audit Contractor) is quality-focused retrospective; SMRC (Supplemental Medical Review Contractor) handles special-topic reviews. An open audit is a minimum -1.0x EBITDA discount; a settled audit with payment plan is -0.25x to -0.5x. Hospice cap recoupment risk deserves its own bucket: aggregate cap equals FY rate ($35,361.44 in FY2026) times beneficiary count under the proportional method, so a hospice with 300 unique beneficiaries faces ~$10.6 million cap. A hospice with average length of stay 180+ days frequently breaches cap; ALOS 200+ days is severe cap-recoupment territory where buyers demand escrow at 100-200% of estimated cap exposure for 3 cap years. The sweet spot for hospice ALOS is 90-110 days where cap risk is minimal and margins are healthy. License-transferability and CHOW holdbacks: CMS 855A Change of Ownership runs 4-12 months typical for full approval, with cash flows continuing under seller PTAN during transition and novation post-close; state license transfer runs 60-180 days typical but varies wildly (NY can be 12+ months; FL 30-60 days). Buyers typically hold back 5-15% of purchase price contingent on full license plus 855A approval plus payer enrollment transitions. Earnout structures are sub-vertical specific: home-health uses visit-based earnouts, hospice uses ADC-based earnouts, home-care uses hours-based or revenue-based earnouts, with typical earnout 10-25% of headline purchase price over 18-36 months with caps; quality earnouts pay tied to maintaining or improving star ratings or HHVBP performance.

DOJ False Claims Act and CMS audit tail liability bucket sizing

The earnout structures sellers actually see in 2026

Why California platform-quality home-health and hospice sellers price at 9-15x and add-ons at 4-9x

The platform-vs-add-on pricing gap in home-health / home-care / hospice M&A is the single biggest source of seller value. The post-PDGM reset in 2020 and the post-VBID end December 31 2024 collectively mean add-ons get crushed unless they have specific capabilities the platform needs. Add-on pricing 2024-2026: home-care add-ons price 4-7x EBITDA into PE platforms (Help at Home, BAYADA nonprofit, AccentCare, Care Advantage) adding geographic density, Medicaid HCBS license, or VA Aid & Attendance certification. Home-health add-ons price 6-9x EBITDA into PE platforms (Elara Caring, BrightSpring, AccentCare) or strategics (Pennant, Aveanna, Addus, CenterWell, Optum) adding CON-state license, Medicare-certified branch, or specialty service line. Hospice add-ons price 8-11x EBITDA into PE platforms (Bristol Hospice under Webster Equity, Gentiva under CD&R + Humana, Three Oaks under Martis since October 2024, AccentCare under Advent International, Care Hospice) or strategics (VITAS, Compassus, Optum-Amedisys) adding CON-state license, state-specific market depth, or ADC growth. Platform pricing 2024-2026: home-care platforms at $25M+ EBITDA price 8-11x EBITDA with TEAM Services at 10x ($3 billion / ~$300M EBITDA April 2026) anchoring; home-health platforms at $25M+ EBITDA price 9-12x EBITDA with Enhabit at 10.2x ($1.1 billion / $108M EBITDA May 2026) anchoring (LHC Group at $5.4 billion / 16-17x EBITDA in Feb 2023 was the pre-PDGM-stabilization comp); hospice platforms at $25M+ EBITDA price 11-15x EBITDA with Bristol Hospice marketed on $140M EBITDA with sponsor bids topping $1 billion in March 2026. Ten characteristics convert an add-on into a platform: multi-state license footprint (3+ states with active operations and 855A approvals), 4+ star Medicare rating (home health) or 4+ overall hospice quality rating, diversified payer mix (no single payer >40%), EMR / clinical documentation on enterprise system (Homecare Homebase, MatrixCare, WellSky, Axxess, or Netsmart — NOT homegrown paper-based), centralized operations team (separate compliance, clinical, billing/RCM, HR), documented PDGM/HOPE/HHVBP performance history, caregiver acquisition and retention infrastructure, Stark/AKS compliance program (HHS-OIG 7-element program documented), branch consolidation completed, and senior leadership independent of the founder.

The ten conversion levers that move you from add-on to platform

Named buyers actively acquiring California home-health, home-care, and hospice businesses in 2026

The buyer pool fractures sharply by sub-vertical with twenty named PE corrections vs commonly-stated data that owners need to know before the data room opens. Public strategics: UnitedHealth Group / Optum (NYSE: UNH, Minnetonka MN) closed the $5.4 billion LHC Group acquisition on February 22 2023 and closed the $3.3 billion Amedisys acquisition on August 7-14 2025 after the Maryland federal court approved a DOJ settlement requiring 164 location divestitures across 19 states ($528M annualized revenue) — the deal is closed, NOT pending and NOT blocked. Encompass Health (NYSE: EHC, Birmingham AL) is the inpatient rehab pure-play post-Enhabit spin. Enhabit (formerly NYSE: EHAB) went private to Kinderhook Industries on May 18 2026 at $1.1 billion / $13.80 per share / 10.2x trailing EBITDA on ~$108M EBITDA and ~$1.06B revenue. The August 2023 strategic review failed to find a buyer; the Kinderhook deal followed AREX Capital activism. Aveanna Healthcare (NASDAQ: AVAH) is Bain Capital + JH Whitney controlled, IPO’d April 2021, pediatric-focused with the Thrive Skilled Pediatric Care acquisition closing June 4 2025 (23 pediatric locations across AZ, GA, KS, NM, NC, VA, TX). Addus HomeCare (NASDAQ: ADUS) closed the Gentiva personal care acquisition for $350 million on December 2 2024 ($280M annualized revenue across AZ, AR, CA, MO, NC, TN, TX, 16,000+ daily consumers) and the Helping Hands Home Care Western PA acquisition for $21.3M on August 1 2025. Pennant Group (NASDAQ: PNTG) made history by closing the $146.5 million acquisition of 54 UnitedHealth/Amedisys divested locations on October 1 2025 (the “largest transaction in our history” per Pennant 8-K). Chemed Corporation (NYSE: CHE) operates VITAS Healthcare hospice plus Roto-Rooter. CenterWell (Humana NYSE: HUM) acquired Intrepid USA Q3 2024 adding 30 net new branches and 200+ field clinicians. PE-sponsored and privately-held platforms: BAYADA Home Health Care is a nonprofit 501(c)(3) foundation since January 2019, NOT CVC Capital, NOT any PE sponsor — this is the most common error in the M&A press for this sector. Recent BAYADA transactions include Holy Redeemer two home-health-plus-hospice businesses (October 30 2024) and a Universal Health Services JV announced 2025 (not a buyout). Help at Home has been Centerbridge Partners + The Vistria Group since November 2020 and is exploring a $3 billion+ exit per early 2026 reports. Compassus is TowerBrook Capital Partners 50% + Ascension Health 50% (NOT OptumHealth) with the OhioHealth at Home JV (September 2024, 3 hospice + 4 home health) and the Providence Health JV (October 2024, 24 home-health + 17 hospice/palliative across AK/CA/OR/TX/WA, Oregon approval May 18 2026). Bristol Hospice is Webster Equity Partners and ran an active auction launched February 2026 by Goldman Sachs + Houlihan Lokey (later Goldman + Guggenheim) marketed on $140 million EBITDA with sponsor bids topping $1 billion. AccentCare is Advent International, post the Seasons Hospice & Palliative Care combination, with 225+ sites in 26 states and 30,000 employees. Gentiva is Clayton, Dubilier & Rice (60%) + Humana (40%); Curo Health Services was fully absorbed into Gentiva and the Curo brand was retired. Three Oaks Hospice is Martis Capital since ~October 2024 ($150M transaction), NOT Cressey & Co. (which exited). VitalCaring is Vistria + Nautic Partners + Anthony Family Investment Partners and acquired Traditions Health home-health + hospice + palliative in late 2025 (75+ locations in OK/TX/KS/MO); NOTE that VitalCaring carries a 43% future-profits decree to Encompass Health/Enhabit per a December 2024 Delaware federal court order ($43.1M atty fees + damages collected February 2026), which materially affects platform valuation. Comfort Keepers is Halifax Group since September 2023 (Sodexo divested entire Worldwide Home Care division). Senior Helpers is Advocate Aurora Enterprises since April 1 2021 (~$180M deal, 320+ franchise + corporate locations, 44 states). Home Instead was acquired by Honor in August 2021; Honor is backed by Andreessen Horowitz, Baillie Gifford, T. Rowe Price — NOT KKR. Synergy HomeCare franchisor is Levine Leichtman Capital Partners since January 21 2025 (NexPhase Capital exited; LLCP is third PE sponsor). HomeWell Care Services is Main Post Partners since January 21 2026 (first PE sponsor for the 138-agency franchise across 37 states with $100M 2024 system-wide revenue). HouseWorks is INDEPENDENT (NOT BAYADA-owned), with AccordCare CT personal care plus Bridge City Home Care (Pittsburgh) closing in 2024 driving revenue from $40M to $400M in 12 months. CareCentrix is Sycamore Partners + Pessina family post Walgreens take-private August 28 2025. BrightSpring (NASDAQ: BTSG) acquired 107 of the UnitedHealth/Amedisys divested locations for $239 million on October 1 2025 (implying ~1.4x revenue). Elara Caring received an Ares Management + DaVita strategic minority investment announced February 2 2026 with focus on home-based kidney care (close expected later 2026).

Public strategics with active US bolt-on posture

PE-sponsored / privately-held platforms with active deal posture

Sub-vertical mix is the variable you can manage in 18 months

Sub-vertical mix is the most important variable a seller can manage in the 18-24 months before a sale because the buyer pool, the multiple band, and the CMS reimbursement mechanics all fracture by sub-vertical. Medicare-certified home-health: top buyers are UnitedHealth/Optum (LHC + Amedisys integrated), CenterWell (Humana), BAYADA (nonprofit), AccentCare (Advent), Elara Caring (Ares + DaVita), BrightSpring, Aveanna, Addus, Enhabit (now Kinderhook), Encompass Health, and regional independents. Multiples run 9-12x EBITDA for platforms post-PDGM reset. Non-medical home-care: top buyers are Help at Home (Centerbridge + Vistria), BAYADA, Honor/Home Instead (a16z + Baillie Gifford + T. Rowe Price), Comfort Keepers (Halifax since September 2023), Right at Home, Synergy HomeCare (LLCP since January 2025), Visiting Angels, Touching Hearts at Home, HomeWell (Main Post since January 2026), and TEAM Services Group (General Atlantic since April 2026). Multiples run 8-11x EBITDA for platforms. Hospice: top buyers are Bristol Hospice (Webster Equity), Compassus (TowerBrook + Ascension 50/50), VITAS Healthcare (Chemed), AccentCare (Advent), Three Oaks Hospice (Martis since October 2024), Care Hospice, Aveanna Hospice, Addus Hospice, and Gentiva (CD&R 60% + Humana 40%). Multiples run 11-15x EBITDA for platforms because of per-diem economics and 20-35% EBITDA margins. Medicaid HCBS waiver specialists: Help at Home, BAYADA, ResCare/BrightSpring dominate. Pediatric home-health: Aveanna and BAYADA dominate via PDN (Private Duty Nursing) and EPSDT Medicaid. Specialty TBI / vent-dependent / complex pediatric: Aveanna and Maxim Healthcare Services lead. The most consequential sub-vertical fracture for sellers to manage is the home-health vs hospice split: bundled home-health-plus-hospice operations achieve 9-11x EBITDA at platform level (Enhabit comp), but pure-play hospice trades 11-15x (Bristol comp), so sellers with strong hospice books that mix home-health may be leaving 2-4 turns of multiple on the table by selling the bundle vs separately positioning the hospice ADC.

Regulatory and licensing landscape for California home-health, home-care, and hospice sales

US federal regulatory layer: CMS 855A Medicare enrollment plus state license is the baseline for both home-health and hospice operations; the Change of Ownership (CHOW) process under 42 CFR 489.18 runs 4-12 months typical for full approval with cash flows continuing under the seller PTAN during transition and novation post-close. Home Health Value-Based Purchasing (HHVBP) expanded nationwide January 1 2025 with +/-5% payment adjustment based on quality performance; the CY2026 measure set was updated effective January 1 2026. Hospice Outcomes & Patient Evaluation (HOPE) assessment tool replaces the Hospice Item Set (HIS) effective October 1 2025; hospices face a 4% APU (Annual Payment Update) reduction if less than 90% of HOPE records are submitted within 30 days. OASIS-E (Outcome and Assessment Information Set) is the current home-health assessment tool (updated from OASIS-D January 1 2023). VBID Hospice carve-in DISCONTINUED December 31 2024 with the full VBID model ending December 31 2025; CMS cited “operational challenges, limited and decreasing participation among MAOs” plus $2.3 billion annual model cost. From January 1 2026 onward, hospice care reverts to FFS Medicare regardless of MA enrollment. Electronic Visit Verification (EVV) compliance under the 21st Century Cures Act 2016 was required by January 1 2020 for personal care services and January 1 2023 for home-health services; non-compliant states face FMAP reductions and state Medicaid recoupment exposure flows down to agencies. DOL Companionship Exemption regulations were narrowed by Home Care Association of America v. Weil 2015; subsequent litigation continues to test employer obligations. State licensing: every state requires a home-health license; the CON (Certificate of Need) states for home-health include North Carolina, Georgia, Alabama, Mississippi, Kentucky, West Virginia, Arkansas, Illinois, Michigan, New Jersey, New York, Ohio, Pennsylvania, South Carolina, Tennessee, Virginia, Washington, and several others; CON-state licenses are a major moat for incumbents because new entrants face approval risk and 6-18 month timelines. State Medicaid HCBS waiver program participation requirements vary by state; the 1915(c) waivers are state-by-state and the 1115 demonstration waivers add another layer. State minimum-wage carve-outs for home-care workers include California SB 525 (healthcare worker minimum wage signed October 13 2023, effective for most facilities October 16 2024, scaling to $25 per hour over 2-9 years; home-health agencies are covered), New York Wage Parity Law (~$23.19 per hour total compensation in NYC FY2026 base wage + benefit), Washington WA Cares Fund (0.58% employee payroll tax effective July 1 2023 with benefits starting July 2026 up to $100 per day lifetime cap $36,500), Massachusetts PCA program wages, and Illinois Domestic Workers Bill of Rights. State Medicaid managed long-term services and supports (MLTSS) programs concentrate buyer interest because contracted MCO networks create scale benefits: Pennsylvania Community HealthChoices since January 2018, New Jersey MLTSS via 5 MCOs since 2014, Virginia CCC Plus since 2017, Tennessee CHOICES, Arizona ALTCS (single managed care plan model where consumers receive both LTSS and medical/behavioral benefits via ONE MCO), Wisconsin Family Care via 6 MCOs, Texas STAR+PLUS with new contracts effective September 1 2024, and Oklahoma SoonerSelect MLTSS launching 2024-2026.

The federal regulatory layer every California home-health, home-care, and hospice seller faces

The CMS 855A Change of Ownership timeline — the hidden California closing-timeline risk

The CMS 855A Change of Ownership (CHOW) process under 42 CFR 489.18 is the most under-discussed timing variable in home-health and hospice M&A. Routine CHOW novation runs 4-12 months for full approval, with cash flows continuing under the seller PTAN during transition. State license transfer adds a parallel timeline: 60-180 days typical, but ranging from 30-60 days in Florida to 12+ months in New York.

The mechanics in California are state-specific. The seller and buyer file a CHOW notification with the CMS regional office and the state health department; the seller continues to bill Medicare and Medicaid under the existing PTAN and license during the transition; the buyer assumes operational and quality control while waiting for novation approval; and the actual 855A approval reassigns the provider number to the buyer entity. During the transition period, the buyer is exposed to seller-source liabilities (FCA, audit findings, cap recoupment) without the legal protection of the new provider number.

Three structural choices for handling CHOW in California:

Pre-sale, the highest-ROI CHOW preparation is to engage the CMS regional office 12-18 months pre-LOI to map the 855A novation process, identify any open ZPIC/UPIC/RAC/SMRC audits that need to be cleared before CHOW, and remediate any state DEP enforcement actions or license-renewal conditions.

DOJ False Claims Act tail liability and hospice cap recoupment risk

The single biggest indemnity bucket in home-health and hospice deals is the DOJ False Claims Act (FCA) tail liability plus the CMS hospice cap recoupment risk. Standard environmental indemnity caps in home-health and hospice M&A run 30-50% of purchase price (vs 10-15% for general R&W indemnification) with 5-7 year survival periods because the FCA and cap exposures persist materially beyond closing.

Named hospice FCA precedents that drive buyer-side underwrite: Traditions Health paid $34 million in October 2024 for non-medically necessary home-health services plus physician-medical-director kickbacks (the FCA was followed by a distressed sale to VitalCaring in December 2025). AccentCare / Guardian Hospice / Guardian Home Care paid $3 million in 2024 in Georgia for non-terminal hospice patients (whistleblowers received $510K). Hospice Compassus paid $3.9 million in 2014 in Tennessee and Virginia. Curo Health Services paid $25 million historically pre-Humana acquisition.

For hospice cap recoupment specifically: the FY2026 hospice cap is $35,361.44 per beneficiary (up 2.7% from $34,465.34 FY2025). Aggregate cap equals FY rate times beneficiary count under the proportional method, so a hospice with 300 unique beneficiaries faces approximately $10.6 million cap. A hospice with average length of stay above 180 days frequently breaches cap; ALOS 200+ days is severe cap-recoupment territory where buyers demand escrow at 100-200% of estimated cap exposure for 3 cap years. The sweet spot for hospice ALOS is 90-110 days where cap risk is minimal and margins are healthy.

Pre-sale, the highest-ROI FCA and cap workstream is to engage outside healthcare regulatory counsel 18 months before the data room to audit physician medical director arrangements (the most common FCA finding), marketing relationships with referral sources (the second most common), high-acuity non-cancer hospice admissions with documentation of terminal prognosis, and ALOS trajectory by referring physician.

Deal mechanics specific to California home-health, home-care, and hospice sales

Tax structures: the 338(h)(10) election for S-corp asset sales is the most common structure when the buyer is a strategic or PE platform; F-reorganization for S-corps with QSubs dominates the Optum / CenterWell / Amedisys-platform bolt-on lane because it preserves S-corp basis step-up while moving operating assets cleanly. CHOW 855A timeline is the deal-defining variable: 4-12 months typical for full approval, with cash flows continuing under the seller PTAN during transition and novation post-close; some state licenses transfer in 30-60 days (FL) while others run 12+ months (NY). Buyers typically structure 5-15% of purchase price as a holdback tied to CHOW completion plus state license transfer plus payer enrollment transitions. Stark Law and Anti-Kickback Statute (AKS) compliance audit: the most common AKS findings in home-health are physician medical director arrangements that fail fair-market-value documentation, marketing arrangements with referral sources that cross AKS safe harbor lines, and overpayment situations triggering 60-day repayment obligations. DOJ False Claims Act tail liability is the single biggest environmental indemnity bucket in hospice deals: open whistleblower complaints create material adverse change risk, settled FCA matters require disclosure schedules with historical settlement amounts, and ongoing UPIC/ZPIC/RAC/SMRC audits flow into a separate indemnity carve-out from the general R&W cap. ZPIC / UPIC / RAC / SMRC / TPE audit history disclosure: sellers must produce open audit documentation, historical audit findings with payment plans, and any administrative appeals pending; an open audit is a minimum -1.0x EBITDA discount, a settled audit with payment plan is -0.25x to -0.5x. License-bound contracts: hospital partnerships, SNF partnerships, ACO contracts, and Medicare Advantage contracts often have anti-assignment clauses requiring counterparty consent for CHOW; sophisticated buyers run the counterparty consent waterfall before LOI. Caregiver workforce: W-2 vs 1099 risk: home-care 1099 misclassification exposure is the single biggest non-FCA tail liability in California (Care Specialist HCS $10M+ judgment 2024-2025 from CA AG) and Pennsylvania (Amazing Care Home Healthcare Services federal court summary judgment 2026). Hospice cap recoupment liability transfer: the cap liability follows the entity, not the seller individuals, so any seller with historical cap exposure transfers that to the buyer at closing — buyers typically demand escrow at 100-200% of estimated cap exposure for 3 cap years. R&W insurance: standard for deals above $25M enterprise value, with environmental indemnity (FCA + audit + cap) typically carved out from R&W cap into a standalone bucket with 30-50% of purchase price cap and 5-7 year survival.

Tax structure choices

The 855A CHOW timeline problem that ambushes asset sales

Caregiver workforce, turnover, and 1099 vs W-2 classification

Caregiver workforce dynamics drive home-health, home-care, and hospice valuation in ways that buyers price aggressively. Industry-baseline turnover runs 75-90% annually in home-care and 40-60% in home-health; sellers who get below 75% (HC) or 60% (HH) clear the platform-quality benchmark. Hospice runs in the 30-50% range for clinical staff (RN, MSW, chaplain) which is structurally lower than home-health.

The 1099 vs W-2 classification question is the single biggest non-FCA tail liability in home-care M&A. California is the most aggressive enforcement state: the California Attorney General won a $10+ million judgment against Care Specialist HCS in 2024-2025 for misclassifying hundreds of home-care workers as 1099 independent contractors. Pennsylvania federal court entered summary judgment against Amazing Care Home Healthcare Services in 2026 for misclassifying LPNs and HHAs as 1099 contractors. Buyer-side QofE routinely runs 1099 sampling audits and any seller with material 1099 misclassification exposure faces either deal-breaker risk or 30-50% purchase-price indemnity carve-outs.

Pre-sale, the highest-ROI caregiver workforce moves are: convert 1099 contractors to W-2 employees 18 months before the data room (the IRS Section 530 safe harbor does not apply to home-care); implement a documented retention program (signing bonuses, referral bonuses, paid training, career ladders) targeting industry-leading turnover; document caregiver training and qualification files for QofE audit; and verify state caregiver registry compliance (CA CDSS Home Care Aide Registry, NY HHA Registry, etc.).

Customer concentration, referral-source concentration, and payer mix

The single most common reason a California home-health, home-care, or hospice deal gets re-priced or canceled at QofE stage is customer or referral-source concentration. Most PE platforms will not pay the platform multiple if the top-1 referral source exceeds 25% of revenue or top-5 exceed 50%. Hospital systems, SNF networks, ACO contracts, and Medicare Advantage plans each count as one customer regardless of patient count.

Payer mix concentration is the parallel issue. Single-payer concentration above 50% Medicare or 50% Medicaid triggers a 0.5-1.5x multiple haircut. The platform-quality benchmark is diversified payer mix: 50-65% Medicare + 15-30% Medicare Advantage + 10-20% Medicaid HCBS + 5-15% private pay. Sellers with 75%+ Medicaid exposure (common in home-care) face the steepest discount because Medicaid rate-compression risk is structural.

The pre-sale fix is straightforward but takes 18-24 months: intentionally diversify referral sources by adding 2-3 net new hospital partnerships or SNF networks, win 1-2 ACO contracts to expand the value-based-care book, and grow Medicare Advantage contracts to dilute the FFS Medicare concentration. A seller that goes from 40% top-1 referral source down to 18% top-1 over 18 months adds 0.5 to 1.5 turns of multiple at exit.

The 18-24 month pre-sale playbook for California home-health, home-care, and hospice sellers

The 18-24 month pre-sale playbook for a home-health, home-care, or hospice business has nine workstreams that compound into 1-3 turns of additional multiple. CMS audit history cleanup: pull historical UPIC / ZPIC / RAC / SMRC / TPE audit findings, remediate any outstanding payment plans, and close out administrative appeals before the data room opens. Medicare star rating optimization: a 3-star home-health agency that climbs to 4 stars over 18 months adds 0.5-1.0 turn of multiple; OASIS-E accuracy, timely initiation of care, drug-education metrics, and patient experience scores are the highest-leverage drivers. For hospice, the 4+ overall quality rating depends on HOPE assessment compliance (4% APU penalty if <90% timely submission). Caregiver turnover reduction: industry benchmark home-care turnover runs 75-90% annually, home-health 40-60%; sellers who get below 60% (HH) or below 75% (HC) clear the platform-quality benchmark. CHOW pre-clearance with CMS regional office: sellers who engage the CMS regional office 12-18 months pre-LOI to map the 855A novation process clear deals 4-8 months faster than sellers who start at LOI. State Medicaid HCBS contract renewals: sellers who clear the renewal pipeline 12+ months out remove a major buyer-side underwrite concern. Compliance program documentation (HHS-OIG 7 elements): written policies, compliance officer, training programs, communication mechanisms, monitoring/auditing, enforcement standards, and corrective action protocols all need to be documented to platform standard. Stark/AKS compliance audit: outside counsel review of physician medical director arrangements, marketing relationships, and joint venture structures within 18 months pre-sale. EMR / clinical doc system standardization: migration to Homecare Homebase, MatrixCare, WellSky, Axxess, or Netsmart from paper or homegrown systems adds 0.5-1.0 turn of multiple and accelerates QofE. Payer diversification: no single payer above 40% (Medicare, Medicare Advantage, Medicaid HCBS, private pay, LTC insurance, VA) is the platform-quality benchmark; sellers with 65%+ Medicare or 60%+ Medicaid see haircut. Branch consolidation analysis: sub-scale branches (typically below $1M annualized revenue or below breakeven margin) drag platform valuation; pre-sale consolidation of 5%+ of branches is often value-accretive.

Data room checklist for California home-health, home-care, and hospice sales

A buyer-ready data room for a California home-health, home-care, or hospice sale should include the following at minimum. Sellers who organize the data room 6 to 12 months before going to market typically clear a higher multiple because the QofE process moves faster and the buyer has fewer reasons to re-price.

Financial documents

Clinical + compliance documents

Workforce documents

Customer + referral documents

The red flags that kill California home-health, home-care, and hospice deals at QofE

Buyers walk away from a meaningful percentage of home-health, home-care, and hospice deals at the QofE stage. The pattern is consistent across the three sub-verticals: the issues that surface in QofE are issues the seller could have remediated 12-18 months earlier at a fraction of the deal cost.

How to start a confidential California home-health, home-care, or hospice sale conversation

If you are exploring a sale of your California Medicare-certified home-health, non-medical home-care, or hospice business, CT Acquisitions runs an introductory conversation that maps your current trailing-12-month revenue and EBITDA to the band-specific buyer pool, identifies the 18-24 month pre-sale workstream priorities for your specific sub-vertical mix, and walks through the named buyers currently active in California at your size band. The conversation is confidential, NDA-protected, and there is no obligation until you decide to engage formally.

The fastest way to move from “sell my home health agency in California” as a search query into a structured sale process is to set up that initial conversation. CT Acquisitions does not list businesses publicly — every introduction to a buyer is intentional, NDA-protected, and named to the specific public strategic or PE platform with active deal posture in your sub-vertical, band, and state.

Frequently asked questions: selling California home-health, home-care, and hospice businesses in 2026

What multiple should I expect for my California home-health, home-care, or hospice business in 2026?

Multiples vary materially by sub-vertical in 2026. Home-health (Medicare-certified): sub-$2M EBITDA owner-operator clears 3.0-6.0x SDE; $2-5M EBITDA mid-market 6.0-8.0x EBITDA; $5-15M EBITDA platform-candidate 8.0-11.0x; $15-50M EBITDA add-on 9.0-12.0x; $50M+ EBITDA strategic 10-12x (capped by Enhabit/Kinderhook 10.2x May 2026 comp). Home-care (non-medical): sub-$2M EBITDA 3.0-5.0x SDE; $2-5M 5.0-7.0x; $5-15M 7.0-9.0x; $15-50M 8.0-10.0x; $50M+ 9.0-11.0x (TEAM Services/General Atlantic ~10x April 2026 anchor). Hospice: sub-$2M single-site 4.0-7.0x EBITDA; $2-5M single-state 7.0-10.0x; $5-15M regional 9.0-12.0x; $15-50M add-on 11.0-14.0x; $50M+ platform 12-15x+ (Bristol Hospice marketed on $140M EBITDA with $1B+ sponsor bids March 2026).

Did the UnitedHealth/Amedisys deal actually close, and how does it affect California sellers?

Yes — the UnitedHealth Optum acquisition of Amedisys for $3.3 billion CLOSED August 7-14 2025 after a Maryland federal court approved a DOJ settlement requiring 164 location divestitures across 19 states ($528M annualized revenue). The DOJ final judgment was entered December 2025. The deal is NOT pending and NOT blocked — many directories still incorrectly list it as pending. The divestitures went to Pennant Group ($146.5M for 54 locations, called “the largest transaction in our history” by Pennant) and BrightSpring ($239M for 107 locations). For California sellers, this means Optum (now integrated LHC+Amedisys) is the largest US home-health strategic and is actively acquiring; Pennant Group is materially stronger in markets where it received divestitures; and BrightSpring has expanded home-health presence.

Is BAYADA owned by CVC Capital or any PE sponsor?

No. BAYADA Home Health Care is a nonprofit 501(c)(3) foundation since January 2019 — NOT CVC Capital, NOT any PE sponsor. This is the most common error in the M&A press for this sector. The nonprofit conversion was done by founder Mark Baiada, who transferred ownership to the BAYADA Heritage Foundation. BAYADA continues to acquire (Holy Redeemer two home-health-plus-hospice businesses October 30 2024; Universal Health Services JV announced 2025) and operates as an active strategic acquirer, but it cannot be sold to PE.

What happened with Enhabit and how does it set the California multiples band?

Enhabit (formerly NYSE: EHAB, the home-health-plus-hospice business that Encompass Health spun out June 30 2022) went PRIVATE to Kinderhook Industries on May 18 2026 at $1.1 billion / $13.80 per share / 10.2x trailing EBITDA on ~$108M EBITDA and ~$1.06B revenue. The August 2023 strategic review failed to find a buyer; the Kinderhook deal followed AREX Capital activism. The transaction definitively reset post-PDGM home-health-plus-hospice platform multiples at the 10x level — this is the single most important comp for any California platform-grade home-health-plus-hospice seller.

How does the hospice cap recoupment risk affect my California hospice sale price?

The FY2026 hospice cap is $35,361.44 per beneficiary (up 2.7% from $34,465.34 FY2025). Aggregate cap equals FY rate times beneficiary count under the proportional method — so a hospice with 300 unique beneficiaries faces approximately $10.6M cap. A hospice with average length of stay (ALOS) above 180 days frequently breaches cap; ALOS 200+ days is severe cap-recoupment territory where buyers demand escrow at 100-200% of estimated cap exposure for 3 cap years. The sweet spot is ALOS 90-110 days where cap risk is minimal and margins are healthy. Pre-sale, document ALOS trajectory by referring physician and remediate any high-acuity non-cancer admissions without terminal-prognosis documentation.

What happened with VBID Hospice carve-in and how does it affect California hospice valuations in 2026?

CMS DISCONTINUED the VBID Hospice carve-in effective December 31 2024, with the full VBID model ending December 31 2025. CMS cited “operational challenges, limited and decreasing participation among MAOs” and the $2.3 billion annual model cost. From January 1 2026 onward, hospice care reverts to FFS Medicare regardless of MA enrollment — a beneficiary on Medicare Advantage who elects hospice becomes FFS Medicare for hospice while staying MA for other services. For California hospice sellers, this removes a layer of payer complexity that had emerged 2021-2024 and simplifies the payer-mix underwrite (FFS Medicare is now the dominant hospice payer).

How does the CHOW 855A timeline affect my California home-health or hospice sale?

The CMS 855A Change of Ownership (CHOW) process under 42 CFR 489.18 runs 4-12 months typical for full approval. Medicare cash flows continue under the seller PTAN during the transition. State license transfer adds a parallel timeline: 60-180 days typical (NY 12+ months; FL 30-60 days). Buyers typically hold back 5-15% of purchase price contingent on CHOW completion plus state license transfer plus payer enrollment transitions. Pre-sale, engage the CMS regional office 12-18 months pre-LOI to map the 855A novation process and identify any open audits that need to be cleared before CHOW. Stock sales preserve 855A continuity (no novation required) but lose buyer asset step-up basis.

What is the DOJ False Claims Act tail liability exposure for California hospice sellers?

DOJ FCA tail liability is the single biggest indemnity bucket in hospice deals. Standard environmental indemnity caps run 30-50% of purchase price (vs 10-15% for general R&W) with 5-7 year survival because FCA exposures persist materially beyond closing. Named precedents: Traditions Health paid $34M October 2024 (non-medically necessary HH services + physician kickbacks; sold to VitalCaring December 2025 as distressed sale); AccentCare/Guardian Hospice paid $3M 2024 in Georgia; VITAS paid $3.9M 2014; Curo Health Services paid $25M historically pre-Humana. The highest-risk FCA areas are physician medical director arrangements without FMV documentation, marketing relationships with referral sources, and high-acuity non-cancer hospice admissions without terminal-prognosis documentation.


CT ACQUISITIONS

Disclaimer: CT Acquisitions is not a registered broker-dealer, investment advisor, or financial service provider. We act solely as a buy-side consultant and independent sponsor source. All information provided on this website is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or investment opportunity. We do not provide legal, tax, or accounting advice. Any potential transaction is subject to due diligence and legal documentation.

© 2025 CT Acquisitions. All Rights Reserved.